Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
Gross to Net Discount for XPOVIO: 31% in Q3 2024, up from 21% in Q3 2023. R&D Expenses: $36.1 million for Q3 2024, compared to $35.6 million for Q3 2023. SG&A Expenses: $27.6 million for Q3 2024, compared to $30.8 million for Q3 2023. Cash & Cash Equivalents: $133.9 million as of September 30, 2024, compared to $192.4 million as of December 31, 2023. Full Year 2024 Revenue Guidance: $145 million to $155 million. Full Year 2024 US XPOVIO Net Product Revenue Guidance: $110 million to $115 million. Full Year 2024 R&D and SG&A Expenses Guidance: $255 million to $265 million. Warning! GuruFocus has detected 7 Warning Signs with KPTI. Release Date: November 05, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Karyopharm Therapeutics Inc ( NASDAQ:KPTI ) reported a favorable regulatory update for their phase three trial in Myelofibrosis, increasing confidence in their trial outcomes. The company achieved its third
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications [Yahoo! Finance]Yahoo! Finance
- Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsPR Newswire
- Karyopharm Therapeutics Provides Endometrial Cancer Program UpdatePR Newswire
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 11/5/24 - Beat
KPTI
Analyst Actions
- 11/1/24 - HC Wainwright
KPTI
Sec Filings
- 12/16/24 - Form DEF
- 12/5/24 - Form PRE
- 12/5/24 - Form 4
- KPTI's page on the SEC website